Skip to main content icon/video/no-internet

Worldwide, 170 million people are infected with the hepatitis C virus (HCV). HCV is the most prevalent bloodborne infection in the United States with an estimated 3.2 million to 3.5 million people chronically infected, and it is the most common cause of chronic liver disease, cirrhosis, and liver cancer in the United States. Although the natural history of chronic HCV infection varies greatly, it is estimated that 60% to 80% of people infected with HCV will develop chronic hepatitis. A majority will eventually develop symptoms or signs of liver damage after an average of 13 years. One third of these people will develop cirrhosis of the liver after an average of 20 years, and 20% to 40% of those who develop cirrhosis will develop liver failure or liver cancer on average 25 to 30 years after initial infection with HCV.

Most HCV infection appears to be transmitted through exposures to infected blood, such as blood transfusions, organ transplants, and injecting drug use. The incidence of HCV infection among blood transfusion recipients has fallen dramatically since 1990, when tests became available for screening blood donors for HCV antibodies. Injecting drug use is now the risk factor most commonly reported by hepatitis C patients and accounts for most HCV transmission in the United States.

Injecting Drug Users and HCV

Prevalence of HCV infection among injecting drug users (IDUs) ranges from 50% to 95%, according to the National Institutes of Health Consensus Development Program. HCV infection usually occurs relatively soon after initiation of injecting drug use with over 50% of IDUs infected in the first year, 75% within 2 years, and over 80% 3 or more years after. Although direct sharing of syringes (i.e., multiperson use of a syringe) is the most efficient method of HCV transmission, sharing of drug preparation equipment (e.g., spoons and cookers for mixing drugs, cotton filters, and water for dissolving drugs or rinsing syringes) may account for a sizable proportion of HCV incidence among IDUs.

Noninjecting Drug Users and HCV

Although the prevalence is much lower than among IDUs, illicit drug users that have never injected (non-IDUs) are also at increased risk for HCV infection. Estimates of HCV prevalence among non-IDUs range from 2% to 35%, according to R. Scheinmann and colleagues. Although there is debate about the mechanisms of HCV infection among non-IDUs, several mechanisms have been implicated, which include engaging in high-risk sexual practices, sharing of non-injection drug paraphernalia, and tattooing. Although HCV is not readily transmitted sexually, sexual transmission does occur. Elevated levels of HCV infection have been observed among patients seeking treatment for sexually transmitted infections (STIs), particularly those that involve genital ulcers such as syphilis, chancroid, and herpes simplex virus type 2. Stimulants such as crack cocaine, powder cocaine, and metham-phetamine have been associated with increased frequency of sex, greater numbers of sexual partners, exchanges involving sex for drugs, higher rates of STIs, and extended duration during sexual encounters, all of which may increase the risk of HCV infection. HIV infection also increases the risk of contracting HCV sexually. Non-IDUs may also increase their risk for HCV infection by sharing of paraphernalia such as straws for snorting or inhaling powder cocaine and pipes for smoking crack cocaine, particularly if they contain small amounts of blood from sores inside the nose from irritations caused by the cocaine or from burns on the lips from crack pipes.

...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles

Sage Recommends

We found other relevant content for you on other Sage platforms.

Loading